ERVW-1 and HIV infectious disease: Since we wanted to eliminate the capacity of the vaccine to target CD4+ T cells as in wild-type HIV infection, we developed one platform in which both EboGP and HIV Env were expressed on the non-replicating virus like particles (VLPs).